Journal of Thrombosis and Haemostasis (J THROMB HAEMOST)

Publisher: International Society on Thrombosis and Haemostasis, Wiley

Journal description

The mission of the new Journal of Thrombosis and Haemostasis will be to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. The Journal publishes high quality, original research reports, state-of-the art reviews, invited commentary and debate on timely topics, letters and announcements. Editors invite both laboratory and clinical reports. The Journal of Thrombosis and Haemostasis is now available in print and online.

Current impact factor: 5.72

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 5.72
2013 Impact Factor 5.55
2012 Impact Factor 6.081
2011 Impact Factor 5.731
2010 Impact Factor 5.439
2009 Impact Factor 6.069
2008 Impact Factor 6.291
2007 Impact Factor 5.947
2006 Impact Factor 5.138
2005 Impact Factor 5.262
2004 Impact Factor 4.831
2003 Impact Factor

Impact factor over time

Impact factor

Additional details

5-year impact 5.59
Cited half-life 5.60
Immediacy index 0.99
Eigenfactor 0.05
Article influence 2.03
Website Journal of Thrombosis and Haemostasis website
Other titles Journal of thrombosis and haemostasis, JTH
ISSN 1538-7933
OCLC 48955697
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • Non-Commercial
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification

Publications in this journal

  • No preview · Article · Nov 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Endothelial von Willebrand factor (VWF) inhibits angiogenesis. Accordingly, blood outgrowth endothelial cells (BOECs) isolated from von Willebrand disease (VWD) patients showed enhanced in vitro angiogenesis when compared with healthy control BOECs. Characterisation of the angiogenic response of VWD BOECs is limited and differences between the different types of VWD have not been investigated in detail. Objectives: The aim of this study was to further explore the potential pathogenic effect of VWF mutations on angiogenesis. Methods: BOECs were isolated from 4 healthy individuals, 10 patients with VWD and 1 heterozygous carrier of a type 2N mutation. Cell migration and tube formation were measured. Results: Migration velocity and total tube formation was similar between VWD patients and controls in general. BOECs from the type 3 VWD patient and one type 2B patient showed increased migratory velocity and tube formation compared with BOECs from other patients and healthy controls. Directional migration was impaired in 8 out of 10 VWD BOECs and the ability to form tubes was limited to early passage numbers, but not for BOECs from healthy controls. Conclusion: BOECs can be a useful tool for ex vivo assessment of endothelial cell function in patients with different types of VWD, but possible limitations, such as early loss of angiogenic capacity, should be recognized. BOECs from most VWD patients consistently showed impairment in the directionality of migration. This is the first report on angiogenic properties of a type 3 VWD BOEC, which showed increased in vitro angiogenesis.
    No preview · Article · Aug 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Despite being a major source of morbidity in patients with deep vein thrombosis (DVT), the perceived importance of post thrombotic syndrome (PTS) as a clinical outcome by physicians is unknown. Aims: To determine whether treating clinicians feel that PTS and severe PTS are a relevant endpoint. Methods: An internet survey was distributed to the members of Thrombosis Canada and The Society of Vascular Surgeons of Canada. The survey was open from Aug. 2014-Oct. 2014. Responses were obtained on a 5 point Likert scale with references: 1(irrelevant), 3 (important) and 5(very important) or as multiple options ‘yes’, ‘no’ or ‘uncertain’. Stastistics calculated by Chi squared analysis. Results: Of the 235 initially contacted 84 (36%) answered the survey (51 internists and 33 vascular surgeons). Any PTS was ranked as significantly less important as an outcome than recurrent DVT, PE during treatment, major bleeding, death, quality of life, venous ulceration and severe PTS (all P < 0.05). No major differences were noted between surgeons and non-surgeons in how they perceived the importance of outcomes except for recurrent DVT, which was ranked as less important by surgeons as compared to internists (P < 0.0001). When presented with the results of the CaVenT study by Enden et al. (Lancet 2012), clinicians were divided on whether a 14% absolute reduction in PTS was clinically relevant, with similar numbers answering: Yes 38%, Uncertain 34%, and No 28% (P = 0.59). There was a trend towards surgeons being more likely to feel that a change of 14% was relevant compared to internists (P = 0.14). Conclusion: Our survey determined that PTS in general is not appreciated as an important endpoint as compared to other clinical outcomes, however, severe PTS is considered important. Results of upcoming DVT treatment studies exploring more aggressive endovascular strategies to prevent PTS may not lead to a change in current practice unless they are adequately powered to show differences in more relevant clinical outcomes, including severe PTS.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin K antagonists have been used as oral anticoagulants in the treatment and prevention of thromboembolic events for over half a century. Although vitamin K antagonists are effective in the management of thromboembolic events, the need for routine monitoring and the associated risk of bleeding has resulted in the development and licensing of direct oral anticoagulants for specific clinical indications. Despite these developments, vitamin K antagonists remain the oral anticoagulants of choice in many clinical conditions. Severe bleeding associated with oral anticoagulation requires urgent reversal. Several options for the reversal of vitamin K antagonist exist, including vitamin K, prothrombin complex concentrates and plasma. In this manuscript, we review current evidence and provide physicians with treatment strategies for more effective management of vitamin K antagonist-associated bleeding. © 2015 International Society on Thrombosis and Haemostasis.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: General awareness of venous thromboembolism (VTE), risk factors and prevention is currently very low in Australia. Patient and their family engagement is critical to improving health care outcomes and reducing health care costs. Aims: To evaluate consumer awareness of VTE risk and assess the importance of the patient point of view on VTE prevention. Methods: In total 1018 Australian people completed a series of online VTE questions in June 2013. Participants requiring surgery or an extended hospital length of stay in the last 3 years, or be planning to have surgery or an extended in-hospital stay in the next 2 years were included. All participants were screened ensuring genuine responses. In the course of the survey VTE was explained to all research participants. Results: Overall 2% of patients were concerned about VTE. Most (30%) patients were more uneasy about the effects of anaesthetic or in-hospital acquired infections. VTE risk was mentioned by a health care provider (HCP) in 36% of cases and was less likely raised in a public (28%) than a private (41%) hospital. It was also more likely to have been mentioned for elective surgery (44%) than for maternity patients (5%). Once participants were aware of the VTE risk, 84% were extremely or very likely to prefer to go to a hospital with ‘best practice’ VTE prevention. This was favoured even if it equated to inconvenience for visitors (42%), further travel (36%), expensive treatment (25%) or changing surgeons (22%). Conclusion: These findings highlight the importance of active discussion between HCP, patients and their families to increase community VTE awareness. Appropriate risk assessment is key to implementing appropriate prophylactic measures. Patient education on their VTE personal risk profile, family history, use of preventative measures and compliance is critical to VTE risk reduction. Engaging clinicians and creating accountable institutions is key to minimising the burden of VTE.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims: To analyse 1) the prevalence and natural history of incidental VTE detected at primary thoracoabdominal staging CT scans in patients with colorectal cancer (CRC), and 2) clinicopathological factors associated with VTE. Methods: All primary staging CT scans with intravenous contrast performed at our Center between 2006 and 2011 were reviewed by an expert radiologist for manifest VTE. Potential confounders were obtained from the Danish Colorectal Cancer Group database, the National Patient and Pathology Registries. Multivariable logistic- and extended Cox-regression analyses were used to adjust for confounders. Results: In 810 of 1287 patients assessed for inclusion, a staging CT scan and data on clinicopathological factors were available. Twentythree patients (2.8%) had a manifest VTE on the scan. Pulmonary, splanchnic and iliofemoral VTE were detected in 15 (1.9%), 6 (0.7%) and 4 (0.5%) patients, respectively. Two patients had VTE at multiple sites. VTE was associated with synchronous metastatic disease (SMD), adjusted odds ratio 2.70 (95% confidence interval (CI):1.15–6.27, P = 0.020), but not statistically associated with gender, age, index tumour location or comorbidity. VTE was associated with an impaired 30-day survival (adjusted Hazard Rate [aHR] = 7.20, 95% CI:2.04– 25.47, P = 0.002), but had no significant impact on long-term survival beyond 30 days (aHR = 1.56, 95% CI:0.79–3.09). Conclusion: Incidental VTE can be detected at routine thoracoabdominal CT scan in the primary staging of nearly 3% of CRC patients and is associated with SMD. The radiologist should endeavour to detect VTE, as they have major impact on 30-day survival. Disclosure of Interest: None declared.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Pancreatic cancer is associated with the highest thrombotic rates (17% to 57%) amongst any other gastrointestinal cancers. Aims: To assess the incidence of thrombotic events, efficacy of thromboprophylaxis and associated bleeding complications. Methods: In total, 182 patients were retrospectively reviewed (2002– 2014) that underwent pancreaticoduodenectomy for benign or confirmed malignancy. Demographics, diagnosis, venous thromboembolism (VTE) risk, hospital length of stay (LOS), operative duration, prophylactic modalities used and bleeding complications were assessed. In-hospital and 1 year readmission rate of all thromboembolic events were evaluated. This included portal vein thrombosis (PVT), upper-extremity deep vein thrombosis (UEDVT), lower extremity deep vein thrombosis (LEDVT) as well as pulmonary embolism (PE). Results: Male to female ratio was 1.4: 1 with a median age of 63 years (55–71) and LOS of 20 days (12–31). Median operative duration was 4.5 h (3.8–6.3). Tumour localisation was mainly in the head of pancreas (39.6%) and ampulla of vater (15.4%). Unfractionated heparin (UH) was used in 84.6% of patients, 7.7% received low molecular weight heparin (LMWH) and 7.7% used UH followed by LMWH. All received mechanical prophylaxis. Major bleeding occurred in 22.7% of patients on UH. In-hospital incidence for thrombosis was 7.1%, 2.2% for PVT, 2.7% for UEDVT, 1.1% for LEDVT and 1.1% for non fatal PE. The 1 year thrombotic incidence was 9.9% with 27.8% of late VTE events detected post hospitalization. VTE accounted for 5.4% of all readmissions. 1 year mortality was 23.1%. Conclusion: The rate of in-hospital thrombotic events was relatively low highlighting the importance of optimal in-hospital thromboprophylaxis relative to risk factors, tumour grade, chemotherapy and/or radiotherapy, operative duration, LOS and bleeding risk. The out of hospital increase in thrombotic events suggests that high risk patients may possibly benefit from post-discharge thromboprophylaxis.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although multislice CT angiography (CTPA) can safely rule out pulmonary embolism (PE) without the need of additional leg ultrasonography (CUS) in outpatients, in a preliminary study we recently observed that in hospitalized patients with suspected PE ruled out by CTPA the prevalence of deep vein thrombosis (DVT) was increased up to six percent. Aims: To provide a more accurate estimate of the prevalence DVT in hospitalized patients with suspected PE ruled out by CTPA. Methods: Prospective single center cohort study. Patients were included if they had developed symptoms compatible with PE more than 48 h after being admitted to hospital for any reason other than PE or more than> 24 h after being admitted for a major surgical intervention (general anesthesia time > 90 min). All participants were evaluated with CTPA (64-slice or greater scanner). Patients were excluded if they had symptoms compatible with PE prior to admission. After providing written consent, all patients were evaluated with bilateral whole leg CUS. Results: Between November 2011 to December 2014, 176 hospitalized patients were included (average 1.1 patients per week). Forty three percent had active cancer, 58% had major surgery and 77.3% were on thrombo-prophylaxis). Shortness of breath was the presenting symptom in 73.3% of the patients, 22.2% had symptoms of DVT and 48.2% had a Wells score > 4 points. The overall prevalence of PE was 35.8% (95% CI 28.7–43.4), and 11% (95% CI 4.5–21.5) in those with a Wells score ≤ 4. The prevalence of proximal DVT was 15.9% (95% CI 7.8–27.2) in those with PE vs. 7.07% (95% CI 3.1–13.4) in those without PE; the incidence of distal DVT 20.6% in those with PE vs. 5.4% in those without PE. In those without PE, the presence of symptoms of DVT increased the risk proximal DVT (RR 5.9; 95% CI 3.2–10.7). Conclusion: Given the high prevalence of proximal DVT in hospitalized patients in whom PE is ruled out by a negative CTPA, a proximal bilateral CUS could be required to safely exclude PE.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis

  • No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Hepatectomy patients are at significant risk of venous thromboembolism (VTE). Pulmonary embolism (PE) rates have been reported to be as high as 6%. Concerns on the use of pharmacological prophylaxis due to post-operative liver dysfunction and bleeding remain an issue. Aims: To determine the incidence of VTE following hepatectomy as well as the efficacy of prophylactic modalities used and associated bleeding complications. Methods: In total, 265 patients were retrospectively reviewed between 2005 to 2014 that underwent hepatectomy for benign or confirmed malignancy. Demographic details, diagnosis, VTE risk, hospital length of stay (LOS), operative details, prophylactic modalities used and bleeding complications were collected and analyzed. Thrombotic events included the in-hospital and 1 year incidence of deep vein thrombosis (DVT), pulmonary embolism (PE) and portal vein thrombosis (PVT). Results: Male to female ratio was 1.4:1 with a median age of 59 years (50–68.5) and LOS of 8 days (6–12). Median operative duration was 4 h (2.9–5.3). The majority (83.1%) of patients underwent surgery for malignancy. All patients received mechanical prophylaxis, 89.5% received unfractionated heparin (UH), 2.6% low molecular weight heparin (LMWH) and 7.9% UH followed by LMWH. 14.7% of patients on UH had a major bleed. The in-hospital thrombotic rate was 1.9%, 0.8% for PVT and 1.1% for non-fatal PE. At 1 year the incidence of thrombotic events was 3.1%, 0.8% for PVT, 0.4% for DVT and 1.9% for non-fatal PE. Post-hepatectomy after discharge VTE accounted for 50% of all events. Mortality at 30 days was 1.1%. Conclusion: The in-hospital VTE rate was kept relatively low with use of prophylactic protocols. Late VTE events occurred after hospitalization with results revealing an almost two fold increase in PE at 1 year. These findings suggest that selective use of post discharge pharmacological prophylaxis post-hepatectomy in patients that are clearly identifiable as high risk may be beneficial.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recommendations for using anticoagulants and endovascular thrombus reduction (ETR) strategies for the treatment of deep vein thrombosis (DVT) and preventing post thrombotic syndrome (PTS) vary between different specialties. Aims: To determine whether there is a difference in the approach to management and prevention of DVT/PTS between internists and vascular surgeons. Methods: A self-completed electronic survey with case scenarios was distributed to members of Thrombosis Canada and the Canadian Society for Vascular Surgery from Aug.-Oct. 2014. Results: Of the 235 contacted, 84 (36%) answered the survey (51 internists and 33 surgeons). For management of ilio-femoral DVT, internists were less likely than surgeons to recommend ETR (45 vs.86%; P = 0.0005), even for scenarios when a patient expressed concern about PTS. In patients with popliteal DVT, both internists and surgeons favour the use of anticoagulation as first line treatment, although surgeons were less likely to prescribe new oral anticoagulants (vs. warfarin) compared to internists (6 vs. 65%; P < 0.0001). A similar proportion of internists and surgeons would recommend the use of ETR in patients with popliteal DVT concerned about PTS. There was no difference in the prescription of graduated compression stockings (GCS) between groups (P = 0.14). Surgeons had better access to endovascular procedures for DVT than internists (97% vs. 53%; P < 0.0001). For surgeons, the primary barrier to prescribing ETR reported was MD unfamiliarity with indications for the procedure (27%), while for internists, it was lack of trained personnel (22%). Conclusion: Our survey found significant practice variation between internists and vascular surgeons for the treatment of DVT and prevention of PTS; both groups continue to frequently use GCS despite the findings of recent studies. Future studies should address how to improve knowledge translation in order to ensure evidence based care is prescribed to patients with DVT regardless of the speciality of the treating physician. Disclosure of Interest: None declared.
    No preview · Article · Jun 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract BACKGROUND: Coagulation factor XII is a serine protease that is important for kinin generation and blood coagulation, cleaving the substrates plasma kallikrein and FXI. OBJECTIVE: To investigate FXII zymogen activation and substrate recognition by determining the crystal structure of the FXII protease domain. METHODS AND RESULTS: A series of recombinant FXII protease constructs were characterized by measurement of cleavage of chromogenic peptide and plasma kallikrein protein substrates. This revealed that the FXII protease construct spanning the light chain has unexpectedly weak proteolytic activity compared to β-FXIIa, which has an additional nine amino acid remnant of the heavy chain present. Consistent with these data, the crystal structure of the light chain protease reveals a zymogen conformation for active site residues Gly193 and Ser195, where the oxyanion hole is absent. The Asp194 side chain salt bridge to Arg73 constitutes an atypical conformation of the 70-loop. In one crystal form, the S1 pocket loops are partially flexible, which is typical of a zymogen. In a second crystal form of the deglycosylated light chain, the S1 pocket loops are ordered, and a short α-helix in the 180-loop of the structure results in an enlarged and distorted S1 pocket with a buried conformation of Asp189, which is critical for P1 Arg substrate recognition. The FXII structures define patches of negative charge surrounding the active site cleft that may be critical for interactions with inhibitors and substrates. CONCLUSIONS: These data provide the first structural basis for understanding FXII substrate recognition and zymogen activation.
    No preview · Article · Mar 2015 · Journal of Thrombosis and Haemostasis

  • No preview · Article · Mar 2015 · Journal of Thrombosis and Haemostasis
  • [Show abstract] [Hide abstract]
    ABSTRACT: The striking coagulopathy in patients with severe sepsis and the increasing insight into the intricate link between inflammation and coagulation has been an inspiration for many researchers and pharmaceutical companies to explore potential therapeutic interventions for severe sepsis [1]. Indeed, in view of the high incidence of severe sepsis and sepsis mortality ranging from 20 to 50%, there is a urgent need for better treatment options [2]. As dysfunctional physiological anticoagulant regulators, such as antithrombin, activated protein C, and tissue factor pathway inhibitor, were shown to be key players in the sepsis-associated activation of coagulation, and animal studies supported the hypothesis that restoration of these pathways resulted in attenuation of coagulopathy and organ dysfunction and reduced mortality, large clinical studies were performed to establish the beneficial effect of these interventions in patients with severe sepsis [2-5]. Although some of these studies demonstrated some advantage in subgroups of patients with most extreme coagulopathies an overall reduction in mortality was not confirmed. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    No preview · Article · Feb 2015 · Journal of Thrombosis and Haemostasis